Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...

Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report...